Mechanistic lessons from the SAVE Study. Survival and Ventricular Enlargement

Area of Science:

• Cardiology
• Pharmacology

Background:

• Left ventricular dysfunction post-myocardial infarction (MI) is associated with poor prognosis.
• Progressive ventricular remodeling contributes to adverse clinical outcomes.
• Angiotensin-converting enzyme (ACE) inhibitors are hypothesized to mitigate these effects.

Purpose of the Study:

• To evaluate the effect of chronic ACE inhibitor (captopril) therapy on clinical outcomes in survivors of MI with left ventricular dysfunction.
• To assess the impact of ACE inhibition on ventricular remodeling and the development of congestive heart failure (CHF).

Main Methods:

• The Survival and Ventricular Enlargement (SAVE) study randomized patients with recent MI and left ventricular dysfunction to captopril or placebo.
• Echocardiography was used in a substudy to assess ventricular dimensions.
• Clinical endpoints including mortality, cardiovascular death, and development of CHF were monitored.

Main Results:

• Randomization to captopril significantly improved overall survival and reduced cardiovascular deaths.
• ACE inhibitor treatment resulted in less ventricular enlargement, as confirmed by echocardiography.
• Fewer patients receiving captopril developed overt congestive heart failure, with a reduction in fatal events post-failure.

Conclusions:

• Chronic ACE inhibitor therapy improves survival and clinical outcomes in patients with left ventricular dysfunction post-MI.
• ACE inhibitors attenuate adverse ventricular remodeling and reduce the incidence and mortality associated with congestive heart failure.
• Findings suggest a role for ACE inhibitors in modifying the renin-angiotensin system's interface with coronary atherosclerotic events.